In another demonstration, the consortium showcased its Journeys visualization dashboard, modeling a laboratory-initiated clinical pathway for chronic kidney disease using cohort data estimated from large real-world data sets. The system quantified averted progression to advanced renal disease, capturing clinical events that were prevented because early diagnostic signals triggered intervention.
Labcorp and PathAI expand collaboration
Labcorp is expanding its relationship with PathAI by deploying PathAI’s AISight Dx FDA-cleared digital pathology platform across its national network of anatomic pathology laboratories and hospital partners.
Through the agreement, Labcorp will provide digital workflows for case management, slide review, collaboration, and annotation. The platform provides artificial intelligence-powered image analysis, secure storage, and system connectivity.
“PathAI’s technology allows us to scale digital pathology nationwide and integrate AI insights into routine care—delivering faster, more consistent results for patients and providers,” said Labcorp’s chief scientific officer, Marcia Eisenberg, PhD, in a press statement.
Labcorp initially invested in PathAI in 2019, and the companies have collaborated on a series of projects, including the deployment of PathAI algorithms in clinical trials.
Quest introduces chat functionality to help patients understand lab test results
Quest Diagnostics has released Quest AI Companion, artificial intelligence-powered chat functionality that helps the company’s patients analyze and act on laboratory test results with their health care providers.
Users can obtain information and pose questions about their test results via Quest’s secure patient mobile app or MyQuest portal and immediately receive personalized explanations.
“The new tool is unique because it seamlessly accesses and analyzes up to five years of an individual’s lab data from Quest results reports to identify trends and patterns that may indicate health risks,” according to a company press release.
Users can prompt the software, which is intended for educational purposes only, to define test names and medical terminology in their results reports and translate the meaning of lab values, as well as assist with composing questions to ask health care providers.
Quest AI Companion is the outcome of a strategic collaboration with Google Cloud and is powered by Google’s Gemini family of AI models.
Beckman Coulter to implement Innovaccer AI platform
The health care artificial intelligence company Innovaccer has announced that Beckman Coulter Diagnostics has selected its enterprise data and AI platform, Gravity, to unify diagnostic, operational, and utilization data across Beckman Coulter instruments, middleware, and enterprise systems.
Among the goals of the partnership are to provide lab leaders with the data, standardized metrics, and actionable insights needed to identify inefficiencies and reduce waste; aggregate and synthesize disparate diagnostic, operational, and utilization data to support evidence-based decision-making across complex laboratory environments; and optimize test utilization by supporting more informed decisions regarding test ordering and availability.
Innovaccer, 510-327-8900
Techcyte AP digital pathology tool gets CE mark under IVDR
Techcyte’s Fusion AP digital pathology platform has received the CE mark under the European In Vitro Diagnostic Regulation (EU) 2017/746 (IVDR) and is approved for clinical use across the European Economic Area.
Fusion AP is designed to support digital pathology workflows by providing slide viewing, enterprise scalability, and integrated artificial intelligence-driven analysis support.
Techcyte, 888-878-3249
PathAI software gets FDA breakthrough device designation
The FDA has granted a breakthrough device designation to PathAI’s PathAssist Derm software for analyzing digital pathology whole slide images of skin lesions and aiding pathologists in their review.
PathAssist Derm is currently classified as being for research use only.